Dan Zandberg
Clinical trials sponsored by Dan Zandberg, explained in plain language.
-
New combo therapy targets Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug, ARRY-614, combined with standard immunotherapies (nivolumab or nivolumab plus ipilimumab) in people with advanced solid tumors like lung, kidney, skin, and head/neck cancers. The first part finds the safest dose, and the second part checks if the comb…
Phase: PHASE1, PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 11, 2026 12:12 UTC
-
New drug cocktail shows promise in shrinking head and neck tumors before surgery
Disease control OngoingThis study tests whether giving immune-boosting drugs before surgery can help shrink head and neck cancer tumors. About 80 adults with advanced but removable cancer will receive either nivolumab alone or combined with relatlimab or ipilimumab. Researchers will monitor side effect…
Phase: PHASE2 • Sponsor: Dan Zandberg • Aim: Disease control
Last updated Jun 03, 2026 12:04 UTC